Table III.
Antibiotic treatment of the enrolled patients with K. pneumoniae UTI.
| Variables | ESBL+ KP (n=34) (%) | ESBL- KP (n=41) (%) | P-value | OR (95% CI) |
|---|---|---|---|---|
| Single antibiotic therapy | 7 (20.5) | 16 (39.0) | 0.0462 | 0.405 (0.143-1.147) |
| 2 antibiotic therapy | 16 (47.0) | 18 (43.9) | 0.3949 | 1.135 (0.455-2.830) |
| ≥3 antibiotic therapy | 11 (32.3) | 7 (17.0) | 0.0683 | 2.323 (0.784-6.877) |
| Most commonly used antibiotics | ||||
| Ciprofloxacin | 6 (17.6) | 21 (51.2) | 0.0014 | 0.204 (0.069-0.597) |
| Ampicillin + sulbactam | 6 (17.6) | 13 (31.7) | 0.0882 | 0.461 (0.153-1.386) |
| 3rd generation cephalosporins | 6 (17.6) | 21 (51.2) | 0.0014 | 0.204 (0.069-0.597) |
| Carbapenems | 18 (52.9) | 6 (14.6) | 0.0002 | 6.562 (2.190-19.657) |
| Amikacin | 19 (55.8) | 7 (17.0) | 0.0002 | 6.152 (2.135-17.728) |
| Trimethoprim/sulfamethoxazole | 5 (14.7) | 8 (19.5) | 0.302 | 0.711 (0.209-2.417) |
| Colistin | 6 (17.6) | 1 (2.4) | 0.0166 | 8.571 (0.977-75.178) |
UTI, urinary tract infections; KB, Klebsiella pneumoniae; ESBL, extended-spectrum β-lactamases; ESBL+ KP, ESBL-producing K. pneumoniae; ESBL- KP, non-ESBL producing KP. OR, odds ratio; CI, confidence interval. Significant P-values are presented in bold print.